Hangzhou Houwu Biopharmaceutical Technology

Hangzhou Houwu Biopharmaceutical Technology is a China-based biotechnology company specializing in the development of targeted protein degradation (TPD) therapies. The company leverages its proprietary Glue-Engine platform to discover and develop small molecule drugs, specifically molecular glues and PROTACs, for oncology and other diseases with high unmet medical needs. Houwu focuses on undruggable targets by utilizing E3 ligase recruitment to selectively degrade disease-causing proteins. Their research primarily targets hematological malignancies and solid tumors through innovative chemical biology approaches. The company is led by an experienced team of drug discovery experts and is supported by leading venture capital firms.